Memorandum of Understanding COVID-19 Consortium

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing announces that it has signed a Memorandum of Understanding...

Update to the Allergy menu

We are excited to announce that our portfolio of allergens has increased to 67. The allergen portfolio now includes the first screening mix to help in...

20 August 2019 - First Order for VISITECT® CD4 Advanced Disease Test

We are excited to announce that we have received our first purchase order for 20,000 units of its VISITECT® CD4 Advanced Disease test from our partner...

19 August 2019 - First order for VISITECT® CD4

We are pleased to announce that we have received a purchase order from our distributor in Nigeria for 50,000 units of VISITECT® CD4. This order is conditional...

12 August 2019 - New CE marked allergens

We have successfully CE marked two additional allergens for the allergy range, increasing the allergy menu to 62 allergens that can be run on the IDS...

18 March 2019 CE-Mark for VISITECT® CD4 Advanced Disease test

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VIS...

06 March 2019 VISITECT CD4 Update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has received its first...

01 March 2019 Board Appointment

OMEGA DIAGNOSTICS GROUP PLC (“Omega” or the “Company” or the “Group”) Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance...

20 April 2018 Allersys Distribution Agreement

Omega announces that it has signed a global distribuon agreement with Immunodiagnostic Systems Limited for its Allersys® range of allergy assays. Click...

Omega Diagnostics and Burnet Institute announce VISITECT® CD4 CE-Marking

Omega Diagnostics, the medical diagnostics company focused on allergy, food intolerance and infectious disease, is delighted to announce it has successfully...